Pardes Biosciences, INC.: insider trades · United States · SEC (Form 4)

About Pardes Biosciences, INC.

Pardes Biosciences, Inc. (ticker: PRDS) is a U.S.-based biopharmaceutical company that was listed on NASDAQ in the United States (United States). The company was built around a drug-discovery strategy combining reversible covalent chemistry with viral biology, with an initial focus on developing novel oral antiviral therapeutics. SEC filings show that Pardes was incorporated in Delaware on February 27, 2020, and that its principal executive office was in Carlsbad, California, placing it squarely within the Southern California biotech cluster. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1822711/000114036123040279/ny20010094x1_exa1a.htm?utm_source=openai)) Pardes’ core historical program was PBI-0451, later referred to as pomotrelvir, an oral direct-acting antiviral designed to inhibit the SARS-CoV-2 main protease (Mpro). The company’s public filings and press materials describe a development path that moved from discovery into the clinic, including the initiation of a first-in-human Phase 1 study in 2021. Strategically, the thesis was to create a convenient oral therapy that could treat or prevent COVID-19, potentially differentiating itself from more complex treatment options through simplicity of administration and a targeted mechanism of action. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1822711/000119312522021684/d299901ds1a.htm?utm_source=openai)) From a competitive standpoint, Pardes was a highly focused small-cap biotech, meaning its market position depended far more on clinical validation, regulatory progress, and capital access than on commercial scale. Companies in this category are typically valued on the basis of pipeline optionality, scientific differentiation, and intellectual property strength, rather than broad product revenue. Pardes therefore fit the profile of a development-stage company whose equity story was driven by execution risk and binary clinical milestones. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1822711/000095017023007860/prds-20221231.htm?utm_source=openai)) Geographically, the company was overwhelmingly U.S.-centric, with operations and leadership anchored in California. Its corporate history is also notable: Pardes reached the public markets through a business combination with FS Development Corp. II, after which the combined entity operated under the Pardes Biosciences name. In 2023, the company’s corporate path changed materially again, with a tender offer and subsequent delisting from NASDAQ, making its recent public-market profile more about corporate actions and ownership disclosures than ongoing listed-company operations. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1822711/000095017023007860/prds-20221231.htm?utm_source=openai)) For investors, PRDS should be viewed primarily as a biotechnology restructuring and event-driven case rather than a conventional commercial pharma company. The most relevant recent developments have centered on insider filings, governance events, and transaction history, while the underlying investment case has historically hinged on the fate of a single lead antiviral asset. That makes Pardes a classic high-risk, high-uncertainty biotech name where regulatory, clinical, and corporate developments matter more than traditional operating metrics. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1822711/000119312523225526/d531376dsc14d9a.htm?utm_source=openai))